Vischioni Barbara, Russo Stefania, Meuli Martino, Bonora Maria, Ronchi Sara, Ingargiola Rossana, Camarda Anna Maria, Imparato Sara, Preda Lorenzo, Ciocca Mario, Molinelli Silvia, Orlandi Ester
Radiation Oncology Clinical Department, National Center for Oncological Hadrontherapy, Pavia, Italy.
Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.
Front Oncol. 2022 Mar 2;12:829502. doi: 10.3389/fonc.2022.829502. eCollection 2022.
The present study aims to evaluate dosimetric and clinical risk factors for the development of maxillary osteoradionecrosis (ORN) in head and neck adenoid cystic carcinoma (ACC) patients treated with carbon ion radiotherapy (CIRT).
Clinical data and treatment plans of ACC patients, consecutively treated from January 2013 to September 2016 within the phase II clinical trial CNAO S9/2012/C, were retrospectively reviewed. ORN and other treatment-related toxicity were graded according to the Common Terminology Criteria for Adverse Events (CTACE), version 4.0. The maxillary bone was contoured on the planning CT, and only patients receiving more than 10% of the prescription dose at their maxilla were considered for the analysis (67 patients). The volumes of maxilla receiving doses from 10 Gy (RBE) to 60 Gy (RBE) (V), with an increment of 10 Gy (RBE), and additional clinical factors were correlated to the incidence of ORN with univariate analysis (Chi-square test). The logistic regression model was subsequently applied for multivariate analysis. Treatment plans calculated with a local effect model (LEM)-based optimization were recalculated with the modified microdosimetric kinetic model (MKM), and compared with literature data from the Japanese experience.
The median time interval from the start of CIRT to ORN appearance was 24 months (range, 8-54 months). Maxillary ORN was observed in 11 patients (16.4%). Grade 1 ORN was observed in 2 patients (18.1%), G2 in 4 (36.3%), G3 in 4 (36.3%) and G4 in 1 (9.3%). From univariate analysis, the site of the tumor, the presence of teeth within the PTV and acute mucositis correlated with the development of maxillary ORN. V were significantly higher for all the dose levels tested in patients with maxillary ORN than patients without necrosis, according to both radiobiological models. The multivariate analysis showed that V60 significantly correlated with ORN risk.
The volume of maxilla irradiated with high dose values was relevant for ORN development in our cohort of ACC patients. These results are in line with previously published data obtained with a different radiobiological model. Our findings might be helpful to prevent the risk of ORN in patients receiving CIRT.
本研究旨在评估接受碳离子放射治疗(CIRT)的头颈部腺样囊性癌(ACC)患者发生上颌骨放射性骨坏死(ORN)的剂量学和临床风险因素。
回顾性分析2013年1月至2016年9月在II期临床试验CNAO S9/2012/C中连续治疗的ACC患者的临床资料和治疗计划。根据不良事件通用术语标准(CTACE)4.0版对ORN和其他治疗相关毒性进行分级。在计划CT上勾勒出上颌骨轮廓,仅将上颌骨接受超过处方剂量10%的患者纳入分析(67例患者)。对接受10 Gy(相对生物效应)至60 Gy(相对生物效应)剂量(V)、增量为10 Gy(相对生物效应)的上颌骨体积以及其他临床因素进行单因素分析(卡方检验),以确定与ORN发生率的相关性。随后应用逻辑回归模型进行多因素分析。使用基于局部效应模型(LEM)优化计算的治疗计划,用改良的微剂量动力学模型(MKM)重新计算,并与日本经验的文献数据进行比较。
从CIRT开始到ORN出现的中位时间间隔为24个月(范围8 - 54个月)。11例患者(16.4%)出现上颌骨ORN。观察到1级ORN 2例(18.1%),2级4例(36.3%),3级4例(36.3%),4级1例(9.3%)。单因素分析显示,肿瘤部位、靶区内牙齿的存在以及急性粘膜炎与上颌骨ORN的发生相关。根据两种放射生物学模型,上颌骨ORN患者在所有测试剂量水平下的V均显著高于无坏死患者。多因素分析显示V60与ORN风险显著相关。
高剂量照射的上颌骨体积与我们队列中的ACC患者ORN发生相关。这些结果与先前使用不同放射生物学模型获得的数据一致。我们的发现可能有助于预防接受CIRT患者的ORN风险。